Sinopharm-SOBERANA COVID-Cienfuegos

Not Applicable

• Conditions: COVID-19; SARS-CoV-2

• Registration Number: RPCEC00000408
• Lead Sponsor: Finlay Vaccine Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-08-16
• Results First Posted: 2022-08-25
• Study Start: 2022-08-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 202

Inclusion Criteria

1.- Subjects with 19 years or more, who were eligible for vaccination with SINOPHARM and SOBERANA Plus in the province of Cienfuegos.
2.- Subjects who give informed consent for blood extraction at the scheduled times.

Exclusion Criteria

1.- Pregnancy, puerperium or lactation.
2.- Subjects with a history of having suffered from COVID-19

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Concentration of specific anti-RBD IgG antibodies. Measurement time: Day 42, 63

Secondary Outcome Measures

Name	Time	Method
% ACE2-RBD inhibition: Measurement time: Day 42, 63<br>Neutralizing antibody titer: Measurement time: Day 42, 63 (sample subset).